Viridian Therapeutics Inc (VRDN) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Viridian Therapeutics Inc stock $5.38, price $28.49, that is 81.1% below the price, quality 35 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range $9.55 – $37.60 · fair‑value band $3.55 – $6.72 · the $28.49 price screens above the $5.38 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Viridian Therapeutics in your weekly email
Every Wednesday you see whether Viridian Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Show moreShow less
It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression.
The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
Stock analysis
Viridian Therapeutics Inc (VRDN) currently trades at $28.49, while our model-based Fair Value estimate is $5.38, 81% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $3.55 (bear) to $6.72 (bull), the price of $28.49 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Viridian Therapeutics Inc reported revenue of $70.8M in FY2025 versus $3.0M in FY2021, a compound +121.1%/yr. Reported net income was −$343M in FY2025.
Key figures
Market cap $3.1B Mid · P/S ratio 46.3 · EPS (TTM) $−3.85 · Return on equity −65.7% · Return on assets (EBIT) −40.5% (5-year average) · Operating margin −44,461% · Revenue (TTM) $71.1M · Revenue growth (YoY) +279%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).
What moves the price
The share trades about 16% below its 52-week high and 114% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −81%, VRDN screens richer than that median.
Fair Value models
Bear$3.55Fair Value $5.38Bull$6.72
Price $28.49 · Downside -81.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham)$4.18$6.33$7.9155
All 1 models by family
Asset-Based
NCAV (Graham)$4.18$6.33$7.9155
The fair value above starts from this blend and is adjusted for dilution from new shares.
In the last 6 months, one officer or director bought shares worth $20.0M, on May 11, 2026. Over the same period, one person sold shares worth $348,194.
SaleJennifer TousignantChief Legal Officer2× since Dec 31, 2025: 16,484 shares, avg. $25.42$418,990Aug 19, 2026
BuyFairmount Healthcare Fund II L.P.Director, 10% owner1,176,470 shares at $17.00$20.0MMay 11, 2026
Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+23,359.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+241.9%
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.8%
’13
’14
’15
’16
’17
’18
’19
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−10,512.4% (2020) → −512.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (91 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
AI conclusion: The biotech's main strength lies in positive phase 3 data for subcutaneous elegrobart and the launch of approved Lumvoa, while its main weak point remains persistent negative cash flow and pre-profit status with ongoing burn.
Main risk: The costs of building a commercial operation in the competitive thyroid eye disease space could weigh on margins as the company stays pre-profit with ongoing cash burn.
Viridian has positive phase 3 data for its subcutaneous elegrobart in chronic thyroid eye disease, with plans for a BLA filing early next year. The approved Lumvoa is already launching, yet the company remains pre-profit with significant cash burn ahead. Our models see it as overvalued. Will the convenience of the new formulation drive enough adoption to offset execution risks in a competitive TED space, or will the costs of building a commercial operation weigh heavier?
Compare Viridian Therapeutics Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score35 · Below median
Fair Value upside−81.1% · Bottom 25%
Profitability
Return on assets−38.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)278.7% · Top 25%
Balance sheet
Debt / equity0.07× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B4.26× · Priciest 25%
P/S (12 months)43.21× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)97· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Viridian Therapeutics Inc (VRDN) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of $5.38 versus a price of $28.49, about 81% lower (overvalued).
What is the fair value of VRDN?
Our model-based fair value for Viridian Therapeutics Inc is $5.38 (as of Nov 5, 2026), built from audited fundamentals. The current price: $28.49.
What is the quality score of VRDN?
Viridian Therapeutics Inc has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Viridian Therapeutics Inc (VRDN)?
Our model-based price target is the fair value of $5.38 (as of Nov 5, 2026) from 1 valuation models. Cautious scenario $3.55, optimistic scenario $6.72. It is a calculation from audited fundamentals, not an analyst target.
What is the Viridian Therapeutics Inc stock forecast for 2026?
Our models put fair value at $5.38, about 81% lower versus a price of $28.49 (overvalued). Cautious scenario $3.55, optimistic scenario $6.72. The calculation is refreshed regularly with new filings.
What is the revenue of Viridian Therapeutics Inc (VRDN)?
Viridian Therapeutics Inc reported trailing-twelve-month revenue of about $71.1M (latest available figure, as of Nov 5, 2026).
What is the intrinsic value of Viridian Therapeutics Inc (VRDN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Viridian Therapeutics Inc it is $5.38 per share (as of Nov 5, 2026), against a price of $28.49. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Viridian Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 5, 2026, VRDN trades above its calculated fair value: price $28.49, fair value $5.38, a gap of about −81% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VRDN?
No. The price is what the market pays today ($28.49); the fair value is what the company's own numbers justify ($5.38). For Viridian Therapeutics Inc the two are $23.11 per share apart. That gap is exactly why we show both numbers side by side.
How much is Viridian Therapeutics Inc worth?
The market values Viridian Therapeutics Inc at about $3.1B (market capitalisation, as of Nov 5, 2026). Per share that is $28.49; our models calculate a fair value of $5.38 per share.
What do the bullish and bearish scenarios say about VRDN?
Our models span a range for Viridian Therapeutics Inc: cautious scenario $3.55, base $5.38, optimistic $6.72 per share (as of Nov 5, 2026, price $28.49). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Viridian Therapeutics Inc (VRDN)?
Balance-sheet figures for Viridian Therapeutics Inc (as of Nov 5, 2026): return on equity −65.7%, debt of 0.07 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is VRDN from its 52-week high?
Viridian Therapeutics Inc trades at $28.49, about 16% below its 52-week high of $33.78 and 114% above the low of $13.30 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $5.38 is for.
Which stocks are comparable to Viridian Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Viridian Therapeutics Inc stock attractive at the current price?
The data as of Nov 5, 2026: price $28.49, calculated fair value $5.38 (−81%), Quality Score 35/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VRDN calculated?
We run Viridian Therapeutics Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $5.38 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Viridian Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Viridian Therapeutics Inc (VRDN)?
The closing price on Nov 6, 2026 was $28.49. Our model-based fair value is $5.38, about 81% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Viridian Therapeutics Inc right now?
The price sits above even our optimistic bull case ($6.72). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($3.55 to $6.72) leaves room in how you read the outcome.
Key figures of Viridian Therapeutics Inc
How large is the market capitalisation of Viridian Therapeutics Inc (VRDN)?
The market capitalisation of Viridian Therapeutics Inc is $3.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Viridian Therapeutics Inc (VRDN)?
The price-to-sales ratio of Viridian Therapeutics Inc is 46.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Viridian Therapeutics Inc (VRDN)?
Earnings per share at Viridian Therapeutics Inc are $−3.85. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Viridian Therapeutics Inc (VRDN)?
The return on equity (ROE) of Viridian Therapeutics Inc is −65.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Viridian Therapeutics Inc (VRDN)?
On an EBIT basis the return on assets of Viridian Therapeutics Inc is −40.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Viridian Therapeutics Inc (VRDN)?
The operating margin of Viridian Therapeutics Inc is −44,461% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Viridian Therapeutics Inc (VRDN)?
Revenue at Viridian Therapeutics Inc is growing +279% versus a year earlier (3y avg +242%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Viridian Therapeutics Inc (VRDN) generate?
The free cash flow of Viridian Therapeutics Inc is −$277M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Viridian Therapeutics Inc (VRDN) hold?
Viridian Therapeutics Inc holds more cash than debt, $162M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Viridian Therapeutics Inc in the live analysis
One click puts Viridian Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 5, 2026
